Literature DB >> 24168445

Hemostatic factors and the metabolic syndrome.

Michael S Kostapanos, Matilda Florentin, Moses S Elisaf, Dimitri P Mikhailidis1.   

Abstract

Metabolic syndrome (MetS) is associated with increased risk of both atherothrombotic cardiovascular events and venous thromboembolism. The pro-thrombotic potential of MetS, may explain this association. In this review we discuss the relationship of MetS with hemostasis focusing on endothelial function, platelet activity, coagulation, fibrinolysis and hemorheologic markers. Endothelial-dependent vasodilatation is impaired in MetS. This is mostly mediated by a reduced expression of vasodilators (nitric oxide and prostacyclin) with a concomitant increase of vasoconstrictors (endothelin- 1, angiotensin II and thromboxane A2). Platelet activity is enhanced in MetS. A cross-talk between activated endothelium and platelets results in a pro-thrombotic vicious cycle. Enhanced coagulation together with impaired fibrinolysis is also present in MetS. This is mirrored by high fibrinogen and plasminogen activator inhibitor-1 levels. Endothelial dysfunction, expressed by high von Willebrand factor and tissue plasminogen factor levels, also contributes to this abnormality. Whole blood and plasma viscosity is increased in MetS. Lifestyle intervention can improve the MetS-related pro-thrombotic state. These measures include weight reduction and improved composition of the diet. A Mediterranean-style diet rich in olive oil, as a source of monounsaturated fat, and low saturated fat consumption may also be beneficial.

Entities:  

Mesh:

Year:  2013        PMID: 24168445     DOI: 10.2174/15701611113116660171

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  11 in total

Review 1.  Clinical Scenario of the Metabolic Syndrome.

Authors:  Swantje Brede; Georg Serfling; Johanna Klement; Sebastian M Schmid; Hendrik Lehnert
Journal:  Visc Med       Date:  2016-09-19

2.  The Effects of Different BMI on Blood Loss and Transfusions in Chinese Patients Undergoing Coronary Artery Bypass Grafting.

Authors:  Mingya Wang; Ming Chen; Hushan Ao; Sipeng Chen; Zhifa Wang
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-02-08       Impact factor: 1.520

3.  Cerebral Cortical Microvascular Rarefaction in Metabolic Syndrome is Dependent on Insulin Resistance and Loss of Nitric Oxide Bioavailability.

Authors:  Paul D Chantler; Carl D Shrader; Lawrence E Tabone; Alexandre C d'Audiffret; Khumara Huseynova; Steven D Brooks; Kayla W Branyan; Kristin A Grogg; Jefferson C Frisbee
Journal:  Microcirculation       Date:  2015-08       Impact factor: 2.628

4.  A low or high BMI is a risk factor for renal hematoma after extracorporeal shock wave lithotripsy for kidney stones.

Authors:  Fabio Nussberger; Beat Roth; Tobias Metzger; Bernhard Kiss; George N Thalmann; Roland Seiler
Journal:  Urolithiasis       Date:  2016-08-30       Impact factor: 3.436

Review 5.  Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.

Authors:  T D Filippatos; K Alexakis; V Mavrikaki; D P Mikhailidis
Journal:  Dig Dis Sci       Date:  2021-01-19       Impact factor: 3.199

6.  Major components of metabolic syndrome and adiponectin levels: a cross-sectional study.

Authors:  Anize D von Frankenberg; Filipe V do Nascimento; Lucas Eduardo Gatelli; Bárbara L Nedel; Sheila P Garcia; Carolina Sv de Oliveira; Pedro Saddi-Rosa; André F Reis; Luis H Canani; Fernando Gerchman
Journal:  Diabetol Metab Syndr       Date:  2014-02-26       Impact factor: 3.320

Review 7.  COSMIC project: consensus on the objectives of the metabolic syndrome in clinic.

Authors:  Juan Pedro-Botet; Juan F Ascaso; Vivencio Barrios; Alejandro De la Sierra; Javier Escalada; Jesús Millán; Jose M Mostaza; Pablo Pérez-Martínez; Xavier Pintó; Jordi Salas-Salvadó; Pedro Valdivielso
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-31       Impact factor: 3.168

8.  Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers - a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale.

Authors:  Michael S Kostapanos; Paul J Cacciottolo; Annette Hubsch; Holly Pavey; James Hurlock; Kaisa Maki-Petaja; Ian B Wilkinson; Joseph Cheriyan
Journal:  J Drug Assess       Date:  2019-10-09

Review 9.  COVID-19 and Oxidative Stress.

Authors:  B V Chernyak; E N Popova; A S Prikhodko; O A Grebenchikov; L A Zinovkina; R A Zinovkin
Journal:  Biochemistry (Mosc)       Date:  2020-12       Impact factor: 2.487

10.  Role of serum fibrinogen levels in patients with rotator cuff tears.

Authors:  Umile Giuseppe Longo; Stefano Petrillo; Alessandra Berton; Filippo Spiezia; Mattia Loppini; Nicola Maffulli; Vincenzo Denaro
Journal:  Int J Endocrinol       Date:  2014-04-10       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.